Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

被引：34

作者：

Ligumsky, Hagai ^{[1
,6
]}

Dor, Herut ^{[6
]}

Etan, Tal ^{[1
]}

Golomb, Inbal ^{[1
,6
]}

Nikolaevski-Berlin, Alla ^{[1
]}

Greenberg, Inbal ^{[6
]}

Halperin, Tamar ^{[2
]}

Angel, Yoel ^{[3
,6
]}

Henig, Oryan ^{[4
,6
]}

Spitzer, Avishay ^{[1
,6
,7
]}

Slobodkin, Marina ^{[5
,6
]}

Wolf, Ido ^{[1
,6
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Oncol Div, IL-6423906 Tel Aviv, Israel

[2] Tel Aviv Sourasky Med Ctr, Human Immunodeficiency Virus Lab, IL-6423906 Tel Aviv, Israel

[3] Tel Aviv Sourasky Med Ctr, Dept Anasthesia Pain & Intens Care, IL-6423906 Tel Aviv, Israel

[4] Tel Aviv Sourasky Med Ctr, Dept Infect Dis & Infect Control, IL-6423906 Tel Aviv, Israel

[5] Tel Aviv Sourasky Med Ctr, Dept Internal Med D, IL-6423906 Tel Aviv, Israel

[6] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[7] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel

来源：

LANCET ONCOLOGY | 2022年 / 23卷 / 02期

关键词：

D O I：

10.1016/S1470-2045(21)00715-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：193 / 195

页数：3

共 10 条

[1] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].

Bar-On, Yinon M. ;

Goldberg, Yair ;

Mandel, Micha ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Kalkstein, Nir ;

Mizrahi, Barak ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Milo, Ron ;

Huppert, Amit .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400

[2] Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment [J].

Eliakim-Raz, Noa ;

Massarweh, Amir ;

Stemmer, Amos ;

Stemmer, Salomon M. .

JAMA ONCOLOGY, 2021, 7 (11) :1716-1718

[3] Waning Immunity after the BNT162b2 Vaccine in Israel [J].

Goldberg, Yair ;

Mandel, Micha ;

Bar-On, Yinon M. ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Haas, Eric J. ;

Milo, Ron ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Huppert, Amit .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) :E85-E85

[4] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients [J].

Ligumsky, Hagai ;

Safadi, Esraa ;

Etan, Tal ;

Vaknin, Noam ;

Waller, Manuel ;

Croll, Assaf ;

Nikolaevski-Berlin, Alla ;

Greenberg, Inbal ;

Halperin, Tami ;

Wasserman, Asaf ;

Galazan, Lior ;

Arber, Nadir ;

Wolf, Ido .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (02) :203-209

[5] Immunogenicity of a BNT162b2 vaccine booster in health-care workers [J].

Saiag, Esther ;

Goldshmidt, Hanoch ;

Sprecher, Eli ;

Ben-Ami, Ronen ;

Bomze, David .

LANCET MICROBE, 2021, 2 (12) :E650-E650

[6]

Siemens Healthcare Diagnositic Inc, 2021, Understanding SARS-CoV-2 IgG immunity thresholds and the process of standardization

[7] An outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections among hospital personnel with high mRNA vaccine uptake [J].

Tene, Yael ;

Levytskyi, Katia ;

Adler, Amos ;

Halutz, Ora ;

Paran, Yael ;

Goldshmidt, Hanoch ;

Itzhaki-Alfia, Ayelet ;

Halperin, Tamar ;

Stepansky, Sarit ;

Ben-Ami, Ronen ;

Henig, Oryan .

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2023, 44 (01) :114-117

[8]

US Food and Drug Administration, 2021, FDA AUTH BOOST DOS P

[9] Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors [J].

Waissengrin, Barliz ;

Agbarya, Abed ;

Safadi, Esraa ;

Padova, Hagit ;

Wol, Ido .

LANCET ONCOLOGY, 2021, 22 (05) :581-583

[10] Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors [J].

Waldhorn, Ithai ;

Holland, Roy ;

Goshen-Lago, Tal ;

Shirman, Yelena ;

Szwarcwort-Cohen, Moran ;

Reiner-Benaim, Anat ;

Shachor-Meyouhas, Yael ;

Hussein, Khetam ;

Fahoum, Liana ;

Peer, Avivit ;

Almog, Ronit ;

Shaked, Yuval ;

Halberthal, Michael ;

Ben-Aharon, Irit .

CANCER DISCOVERY, 2021, 11 (10) :2430-2435

← 1 →